HAVCR2 and non-small cell lung carcinoma: In two NSCLC patients and two mice models of lung adenocarcinoma with anti-PD-1 treatment, the upregulation of TIM-3 was observed, suggesting another mechanism of acquired resistance against anti-PD-1 therapy [55].